Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0YQKRG
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
IMAB362-MC-Val-Cit-PAB-MMAE
|
|||||
| Synonyms |
IMAB362 MC Val Cit PAB MMAE
Click to Show/Hide
|
|||||
| Organization |
RemeGen Co., Ltd.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Gastric cancer [ICD11:2B72]
Investigative
Pancreatic cancer [ICD11:2C10]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4.22
|
|||||
| Structure |
|
|||||
| Antibody Name |
IMAB362
|
Antibody Info | ||||
| Antigen Name |
Claudin-18.2 (CLDN18.2)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
General Information of The Activity Data Related to This ADC
Discovered Using Patient-derived Xenograft Model
| Standard Type | Value | Units | Animal Model (No. of PDX) |
|---|---|---|---|
| Tumor Growth Inhibition value (TGI) |
≈ 63.3
|
%
|
Pancreatic cancer PDX model
|
Revealed Based on the Cell Line Data
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Half Maximal Inhibitory Concentration (IC50) |
501
|
ng/mL
|
NCI-N87 cells
|
Gastric tubular adenocarcinoma
|
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 63.30% (Day 67) | Positive CLDN18.2 expression (CLDN18.2 +++/++) | ||
| Method Description |
Conjugates of the exemplary antibodies were tested using an established PDX model of pancreatic cancer cell implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 5 mg/kg of one of the conjugates listed above or with PBS only.
|
||||
| In Vivo Model | Pancreatic cancer PDX model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 501 ng/mL | Positive CLDN18.2 expression (CLDN18.2 +++/++) | ||
| Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.